Blog, fact sheets detail HIPAA's impact on interoperability

The Office of the National Coordinator for Health IT (ONC) is working to disseminate the idea that HIPAA does not impede interoperability.

Through blog posts and fact sheets, the federal agency is explaining that HIPAA not only protects personal health information from misuse but enables that same information to be "accessed, used or disclosed interoperably, when and where it is needed for patient care," Lucia Savage, ONC's chief privacy officer, and Aja Brooks, an ONC privacy analyst, write in the first post of a four-part series.

The fact sheets were developed with input from the Department of Health and Human Services' Office of Civil Rights (OCR), and include examples of health data shared without authorization or a note from the patient, Savage and Brooks wrote.

This new series of clarification and guidance comes after last month's release by OCR of new guidance on patient data rights under HIPAA.

The first document focuses on "Permitted Uses and Disclosures: Exchange for Health Care Operations" and notes instances in which covered entities can share data with another covered entity or its business associate without prior authorization, including:

  • Conducting quality assessment and improvement activities
  • Developing clinical guidelines
  • Conducting patient safety activities as defined in applicable regulations
  • Conducting population-based activities relating to improving health or reducing health care

The second fact sheet covers the exchange of patient information between or among providers when it comes to treatments. It also reviews the role of business associates when it comes to patient information to create care plans, and the role of the provider and/or health plan in that exchange of data.

"The new fact sheets remind stakeholders through practical, real-life scenarios, that HIPAA supports interoperability because it gives providers permission to share PHI for patient care, quality improvement, population health and other activities," Savage and Brooks wrote.

Read the complete blog post.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.